FDA Rejects Lilly, Avid Alzheimer's Test Dye

Earlier this month, Eli Lilly CEO John Lechleiter predicted the FDA would approve Amyvid, a new molecular imaging agent that could revolutionize Alzheimer's diagnosis by detecting the presence of amyloid plaque in the brain. But the FDA chose to accept an expert panel's recommendation and reject the drug.

The agency had told Lilly to establish a training program to ensure reader accuracy and cons